Status:
UNKNOWN
Investigation of the Use of a Probiotic Supplement in People With Long COVID
Lead Sponsor:
Sheffield Hallam University
Collaborating Sponsors:
Symprove UK
Biomesight
Conditions:
Long COVID
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study is a double-blinded randomised trial to assess the efficacy of a probiotic supplement in alleviating symptoms in people with Long COVID.
Detailed Description
240 participants with Long COVID will be randomly assigned to either a probiotic or placebo group in a 1:1 ratio for twelve weeks. Participants will track symptoms using an app for three weeks before ...
Eligibility Criteria
Inclusion
- Long COVID defined as National Institute for Health and Care Excellence (NICE) criteria for Long COVID (Persistent symptoms at least 12 weeks after a confirmed or suspected Covid-19 infection).
- \-
Exclusion
- Significant co-morbidities - no pre-existing diagnosis of hypertension, diabetes, cerebrovascular, cardiovascular or peripheral vascular disease, coagulopathy or haematological disorder or current or recent cancer.
- \-
Key Trial Info
Start Date :
June 12 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 11 2023
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT05975034
Start Date
June 12 2023
End Date
December 11 2023
Last Update
August 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheffield Hallam University
Sheffield, United Kingdom, S1 1WB